The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine will continue to develop technologies for using artificial intelligence (AI) to diagnose eye diseases, said Andriy Korol, head of the department for studying the biological action and application of lasers in ophthalmology at the clinic.
“We have now worked out diabetic retinopathy, and at the next stage we will develop in several directions. These may include specific eye diseases, retinal diseases, glaucoma, age-related degeneration, and other diseases that are manifestations of diabetes,” he said in an interview with Interfax-Ukraine.
Korol noted that another area of AI technology development that the institute plans to implement will be a system that will allow “to see the symptoms and signs of various diseases, such as hypertension, vascular changes, hereditary diseases, and a number of rare diseases.”
Korol specified that the institute will be able to “launch research on new nosologies every year and a half.”
The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine (Odesa), after the end of the coronavirus (COVID-19) pandemic, intends to resume work on the creation of branches in other countries, Director of the institute Natalia Pasechnikova has said.
“The demand for ophthalmological medical services is growing all over the world. The lack of highly qualified specialists has created the preconditions for the signing of memorandums on the establishment of branches of the institute in other countries [currently in China and Bulgaria]. Unfortunately, this issue is still difficult due to the pandemic. However, I hope that after humanity cope with the pandemic, we will be able to resume these projects,” she said in an interview with Interfax-Ukraine.
According to Pasechnikova, the institute receives offers of cooperation and participation in global international research.
“We have signed agreements on cooperation with organizations and companies in Israel, Switzerland, Germany, Mexico, India, and Hawaii. We cooperate with Linköping University [Sweden] in the development of an artificial cornea; we participate in a global study conducted by the National Institute of Health [U.S.] in the field of research of hereditary ophthalmological diseases and the development of technologies for their diagnosis,” she said.
